STOK (Stoke Therapeutics) Total Current Liabilities: $40.81 Mil (As of Mar. 2026)


STOK Stoke Therapeutics Inc STOK
45 GF Score
Price $31.90
GF Value $10.16
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Stoke Therapeutics Total Current Liabilities?

Stoke Therapeutics STOK +5.09% 45 Total Current Liabilities is $40.81 Mil as of Mar. 2026. GuruFocus rates STOK with a GF Score™ of 45/100 and a GF Value™ of $10.16 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Stoke Therapeutics's total current liabilities for the quarter that ended in Mar. 2026 was $40.81

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Stoke Therapeutics Total Current Liabilities Related Terms

Stoke Therapeutics Total Current Liabilities Historical Data

* Premium members only.

The historical data trend for Stoke Therapeutics's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Stoke Therapeutics Total Current Liabilities Chart

Stoke Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Current Liabilities
Get a 7-Day Free Trial Premium Member Only 17.14 31.39 30.82 40.06 57.88

Stoke Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 44.69 38.68 41.73 57.88 40.81
STOK
45GF Score
Stoke Therapeutics Inc STOK
Total Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Stoke Therapeutics Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Stoke Therapeutics's Total Current Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=27.932+3.007
+Other Current Liabilities+Current Deferred Liabilities
=15.035+11.901
=57.88

Stoke Therapeutics's Total Current Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=23.731+2.433
+Other Current Liabilities+Current Deferred Liabilities
=4.576+10.066
=40.81

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

What does a Total Current Liabilities of $40.81 Mil mean?
Stoke Therapeutics (STOK) has a Total Current Liabilities of $40.81 Mil as of Mar. 2026. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Stoke Therapeutics and its competitors.
Is Stoke Therapeutics' Total Current Liabilities too high?
Stoke Therapeutics' current Total Current Liabilities is $40.81 Mil. Overall, Stoke Therapeutics has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Stoke Therapeutics' Total Current Liabilities compare to SION and RXRX?
Stoke Therapeutics' Total Current Liabilities of $40.81 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Liabilities for a Biotechnology company?
A good Total Current Liabilities depends on the Biotechnology industry context. However, Total Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Liabilities mean?
A high Total Current Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Stoke Therapeutics and its competitors. Stoke Therapeutics's current Total Current Liabilities is $40.81 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stoke Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Stoke Therapeutics (STOK) is currently considered Significantly Overvalued. The stock's GF Value™ is $10.16, compared to a current price of $31.90 — trading 214% above its estimated fair value. The current Total Current Liabilities is $40.81 Mil. Stoke Therapeutics' overall GF Score™ is 45/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Liabilities calculated?
Total Current Liabilities is calculated from a company's financial statements. For Stoke Therapeutics (STOK), the current Total Current Liabilities is $40.81 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Stoke Therapeutics (STOK) Overvalued in 2026?

Based on GuruFocus' analysis, Stoke Therapeutics stock appears to be overvalued. The current stock price of $31.90 is trading 214% above its estimated GF Value™ of $10.16. GuruFocus considers Stoke Therapeutics to be Significantly Overvalued.

Key valuation signals for STOK:

  • Total Current Liabilities: $40.81 Mil
  • GF Value™: $10.16 vs. price of $31.90 (214% above fair value)
  • GF Score™: 45/100 with 5 warning signs

No single metric tells the full story. See the STOK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Stoke Therapeutics Business Description

Other Exchanges 0GT:Germany
Address 45 Wiggins Avenue, Bedford, MA, USA, 01730
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
45GF Score

Get the complete analysis for STOK

Total Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$31.90
Price
$10.16
GF Value